AU2009284098B2 - Pyrrolopyrimidine compounds as CDK inhibitors - Google Patents

Pyrrolopyrimidine compounds as CDK inhibitors Download PDF

Info

Publication number
AU2009284098B2
AU2009284098B2 AU2009284098A AU2009284098A AU2009284098B2 AU 2009284098 B2 AU2009284098 B2 AU 2009284098B2 AU 2009284098 A AU2009284098 A AU 2009284098A AU 2009284098 A AU2009284098 A AU 2009284098A AU 2009284098 B2 AU2009284098 B2 AU 2009284098B2
Authority
AU
Australia
Prior art keywords
cyclopentyl
pyrrolo
carboxylic acid
ylamino
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2009284098A
Other languages
English (en)
Other versions
AU2009284098A1 (en
Inventor
Gilbert Besong
Christopher Thomas Brain
Clinton A. Brooks
Miles Stuart Congreve
Claudio Dagostin
Guo He
Ying Hou
Steven Howard
Bharat Lagu
Yue Li
Yipin Lu
Paul Mortenson
Troy Smith
Moo Sung
Steven Woodhead
Wojciech Wrona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Astex Therapeutics Ltd
Original Assignee
Novartis AG
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009284098(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Astex Therapeutics Ltd filed Critical Novartis AG
Publication of AU2009284098A1 publication Critical patent/AU2009284098A1/en
Application granted granted Critical
Publication of AU2009284098B2 publication Critical patent/AU2009284098B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009284098A 2008-08-22 2009-08-20 Pyrrolopyrimidine compounds as CDK inhibitors Active 2032-10-23 AU2009284098B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9103708P 2008-08-22 2008-08-22
US61/091,037 2008-08-22
PCT/EP2009/060793 WO2010020675A1 (en) 2008-08-22 2009-08-20 Pyrrolopyrimidine compounds as cdk inhibitors

Publications (2)

Publication Number Publication Date
AU2009284098A1 AU2009284098A1 (en) 2010-02-25
AU2009284098B2 true AU2009284098B2 (en) 2012-03-29

Family

ID=41171100

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009284098A Active 2032-10-23 AU2009284098B2 (en) 2008-08-22 2009-08-20 Pyrrolopyrimidine compounds as CDK inhibitors

Country Status (48)

Country Link
US (8) US8685980B2 (https=)
EP (2) EP2331547B1 (https=)
JP (2) JP5560496B2 (https=)
KR (2) KR101353857B1 (https=)
CN (2) CN103788100A (https=)
AR (2) AR073116A1 (https=)
AU (1) AU2009284098B2 (https=)
BR (1) BRPI0917791B1 (https=)
CA (1) CA2734802C (https=)
CL (1) CL2011000306A1 (https=)
CO (1) CO6341561A2 (https=)
CR (1) CR20110101A (https=)
CU (1) CU24062B1 (https=)
CY (2) CY1115703T1 (https=)
DK (1) DK2331547T3 (https=)
DO (1) DOP2011000057A (https=)
EA (1) EA019094B1 (https=)
EC (1) ECSP11010843A (https=)
ES (1) ES2522346T3 (https=)
FR (1) FR17C1059I2 (https=)
GE (1) GEP20135785B (https=)
HN (1) HN2011000542A (https=)
HR (1) HRP20141018T1 (https=)
HU (1) HUS1700051I1 (https=)
IL (1) IL211164A (https=)
JO (1) JO2924B1 (https=)
LT (1) LTC2331547I2 (https=)
LU (1) LUC00048I2 (https=)
MA (1) MA32555B1 (https=)
ME (1) ME01282B (https=)
MX (1) MX2011001879A (https=)
MY (1) MY150560A (https=)
NI (1) NI201100042A (https=)
NL (1) NL300909I2 (https=)
NO (1) NO2017059I1 (https=)
NZ (1) NZ591176A (https=)
PE (1) PE20110419A1 (https=)
PL (1) PL2331547T3 (https=)
PT (1) PT2331547E (https=)
RS (1) RS53574B1 (https=)
SI (1) SI2331547T1 (https=)
SM (1) SMT201500017B (https=)
TN (1) TN2011000062A1 (https=)
TW (1) TWI468409B (https=)
UA (1) UA103628C2 (https=)
UY (2) UY32067A (https=)
WO (1) WO2010020675A1 (https=)
ZA (1) ZA201100994B (https=)

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
EP2558092B1 (en) * 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
JP5959516B2 (ja) 2010-08-18 2016-08-02 ライフ テクノロジーズ コーポレーション 電気化学的検出装置のためのマイクロウェルの化学コーティング法
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
MX338327B (es) * 2010-10-25 2016-04-12 G1 Therapeutics Inc Inhibidores de cdk.
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
AU2014259534B2 (en) * 2011-01-04 2016-05-19 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
PT2661433T (pt) * 2011-01-04 2017-10-24 Novartis Ag Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
EP2726074B1 (en) 2011-07-01 2018-04-04 Novartis AG Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
KR20140040769A (ko) * 2011-07-01 2014-04-03 노파르티스 아게 조합 요법
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US9194840B2 (en) 2012-01-19 2015-11-24 Life Technologies Corporation Sensor arrays and methods for making same
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
CA2870019C (en) * 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
CA2882724A1 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
AU2013296237B2 (en) 2012-08-03 2019-05-16 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
US9867825B2 (en) * 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
EP3696276A1 (en) 2013-02-25 2020-08-19 Novartis AG Novel androgen receptor mutation
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
WO2014159999A1 (en) * 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
WO2014151444A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
US9796708B2 (en) 2013-03-14 2017-10-24 Abbvie Inc. Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
AU2014244194A1 (en) 2013-03-14 2015-09-10 Abbvie Inc. Pyrrolopyrimindine CDK9 kinase inhibitors
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
US20140274896A1 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
CA2906157C (en) * 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
MA38522A1 (fr) 2013-03-21 2017-10-31 Novartis Ag Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
AU2014253932B2 (en) 2013-04-16 2020-04-30 Memorial Sloan-Kettering Cancer Center Companion diagnostic for CDK4 inhibitors
CN105828822B (zh) 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
WO2015031666A1 (en) * 2013-08-28 2015-03-05 Irm Llc Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TW201605857A (zh) * 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
US20160257688A1 (en) * 2013-10-24 2016-09-08 Francis Xavier Tavares Process for Synthesis of Lactams
MX2016006894A (es) * 2013-11-27 2016-08-17 Novartis Ag Terapia de combinacion que comprende un inhibidor de jak, cdk y pim.
US9476853B2 (en) 2013-12-10 2016-10-25 Life Technologies Corporation System and method for forming microwells
WO2015095840A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
CN105848656B (zh) 2013-12-23 2019-10-25 诺华股份有限公司 药物组合
KR20160100975A (ko) * 2013-12-23 2016-08-24 노파르티스 아게 제약 조합물
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
US9796701B2 (en) 2013-12-31 2017-10-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
DK3149008T3 (en) * 2014-05-28 2019-04-01 Shanghai Fochon Pharmaceutical Co Ltd Specific protein kinase inhibitors
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
US10138250B2 (en) 2014-12-12 2018-11-27 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
US9994579B2 (en) 2014-12-12 2018-06-12 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
CN107530292B (zh) 2015-04-16 2022-11-01 诺华股份有限公司 瑞博西尼片剂
CN106146515B (zh) * 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
TWI696617B (zh) * 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
SG11201709837RA (en) 2015-05-29 2017-12-28 Teijin Pharma Ltd PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
CN105037236B (zh) * 2015-06-04 2017-07-28 苏州明锐医药科技有限公司 瑞博西尼中间体及其制备方法
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
CN105130992B (zh) * 2015-07-16 2018-02-09 苏州大学 具有激酶抑制活性的含氮杂环化合物、制备方法和用途
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017037575A1 (en) 2015-08-28 2017-03-09 Novartis Ag A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
EP3340987A1 (en) 2015-08-28 2018-07-04 Novartis AG Combination of ribociclib and dabrafenib for treating or preventing cancer
US20190365741A1 (en) 2015-08-28 2019-12-05 Novartis Ag Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
EP3340990B1 (en) 2015-08-28 2019-09-25 Novartis AG Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
EP3156406A1 (en) 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN106749259B (zh) * 2015-11-19 2019-02-01 华东师范大学 一种环戊基嘧啶并吡咯类化合物的合成方法
CN106831780A (zh) * 2015-12-03 2017-06-13 南开大学 具有cdk4/6和hdac抑制活性的新型杂环衍生物
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
CN105541863B (zh) * 2016-02-16 2017-09-05 安纳康科学股份有限公司 噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
US11921116B2 (en) 2016-03-09 2024-03-05 Memorial Sloan Kettering Cancer Center Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
EP3434676B1 (en) 2016-03-25 2022-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted pyrrolopyrimidine cdk inhibitor, pharmaceutical composition containing same and use thereof
CN107266451B (zh) * 2016-04-07 2021-12-31 上海医药工业研究院 瑞布昔利布中间体的制备方法
EP3445765A4 (en) * 2016-04-22 2019-09-18 Dana Farber Cancer Institute, Inc. DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
KR102374033B1 (ko) 2016-05-07 2022-03-14 상하이 포천 파마슈티컬 씨오 엘티디 특정 단백질 키나제 억제제
CN108290899B (zh) * 2016-06-06 2020-09-18 深圳市塔吉瑞生物医药有限公司 一种取代的吡咯并嘧啶化合物及其应用
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
WO2018005865A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
RU2019102647A (ru) * 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
BR112019003722A2 (pt) 2016-08-23 2019-05-28 Eisai R&D Man Co Ltd terapias de combinação para o tratamento de carcinoma hepatocelular
WO2018051280A1 (en) * 2016-09-15 2018-03-22 Dr. Reddy’S Laboratories Limited Process for preparation of ribociclib, its acid addition salts
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US10849903B2 (en) 2016-10-20 2020-12-01 Pfizer Inc. Anti-proliferative agents for treating PAH
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
US11865176B2 (en) 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3541391A4 (en) * 2016-11-17 2020-06-17 The University of North Carolina at Chapel Hill ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF PREPARING AND USING THE SAME
PE20191133A1 (es) 2016-11-28 2019-09-02 Teijin Pharma Ltd Cristal de derivado de pirido[3,4-d]pirimidina o su solvato
HUE053220T2 (hu) 2016-11-28 2021-06-28 Teijin Pharma Ltd ((Piridin-2-il)-amino)pirido[3,4-d]pirimidin és ((piridazin-3-il)-amino)pirido[3,4-d]pirimidin származékok mint CDK4/6 inhibitorok pl. reumatoid artritisz, érelmeszesedés, tüdõfibrózis, agyi infartus vagy rák kezelésére
KR20190092478A (ko) 2016-12-05 2019-08-07 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
EP3573619A4 (en) * 2017-01-27 2020-10-28 SignalRX Pharmaceuticals, Inc. THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2019010981A (es) 2017-03-16 2020-09-07 Eisai R&D Man Co Ltd Terapias de combinacion para el tratamiento de cancer de mama.
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
CN107118215B (zh) * 2017-05-06 2019-04-05 上海耀大生物科技有限公司 一种治疗乳腺癌药物瑞博西尼中间体的制备方法
CN106946880B (zh) * 2017-05-06 2019-04-26 南京焕然生物科技有限公司 一种制备瑞博西尼中间体的方法
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
CN108929312A (zh) * 2017-05-22 2018-12-04 南开大学 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
CN108929324A (zh) * 2017-05-22 2018-12-04 南开大学 新型1,1-环丙基二酰胺衍生物的制备与应用
TW201906818A (zh) 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
US20200155566A1 (en) 2017-08-03 2020-05-21 Novartis Ag Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
HRP20240026T1 (hr) 2017-08-25 2024-03-29 Assia Chemical Industries Ltd Kruti oblik ribociklib sukcinata
CN111433375B (zh) 2017-08-31 2024-07-30 诺华股份有限公司 选择针对癌症患者的治疗的方法
WO2019062854A1 (zh) * 2017-09-29 2019-04-04 杭州领业医药科技有限公司 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
CN111386272B (zh) * 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
EP3709997A1 (en) 2017-11-16 2020-09-23 Novartis AG Pharmaceutical combination comprising lsz102 and ribociclib
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
US11111250B2 (en) 2017-12-22 2021-09-07 Shilpa Meicare Limited Polymorphs of Ribociclib mono succinate
WO2019126731A1 (en) * 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2019133864A1 (en) * 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
EP3738084A4 (en) 2018-01-08 2021-11-17 G1 Therapeutics, Inc. SUPERIOR G1T38 DOSING SCHEMES
CN107936029B (zh) * 2018-01-08 2020-06-30 南京奇可药业有限公司 一种合成瑞博西尼的方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN111989099A (zh) * 2018-01-29 2020-11-24 贝塔制药有限公司 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途
JP2021514359A (ja) 2018-02-15 2021-06-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． キナーゼ阻害剤としての複素環式化合物
WO2019167068A1 (en) 2018-03-01 2019-09-06 Cipla Limited Novel polymorphs of ribociclib succinate
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
US10723739B2 (en) 2018-05-14 2020-07-28 Apotex Inc. Processes for the preparation of Ribociclib and intermediates thereof
WO2019222521A1 (en) * 2018-05-16 2019-11-21 G1 Therapeutics, Inc. Cdk inhibitors for the treatment of neoplastic disorders
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
AU2019280689B2 (en) 2018-06-05 2024-09-05 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
MX2021000895A (es) 2018-07-27 2021-08-24 California Inst Of Techn Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos.
CA3109605A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
AU2019325685B2 (en) 2018-08-24 2025-07-24 Pharmacosmos Holding A/S Improved synthesis of 1,4-diazaspiro(5.5)undecan-3-one
AU2019338032A1 (en) * 2018-09-13 2021-05-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of substituted pyrrolopyrimidine CDK inhibitor, crystal and use thereof
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
WO2020084389A1 (en) 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CN109400612A (zh) * 2018-12-24 2019-03-01 重庆三圣实业股份有限公司 一种瑞博西尼的制备方法及其产品和用途
WO2020140054A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220056037A1 (en) * 2018-12-28 2022-02-24 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US12390468B2 (en) 2019-01-23 2025-08-19 Novartis Ag Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide
EP3923941B1 (en) 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and ribociclib
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
MA55909A (fr) 2019-05-05 2022-03-16 Qilu Regor Therapeutics Inc Inhibiteurs de cdk
WO2020225827A1 (en) 2019-05-08 2020-11-12 Mylan Laboratories Limited Novel polymorphs of ribociclib succinate
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
KR20220024106A (ko) 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
IL288508B2 (en) * 2019-06-04 2026-02-01 Step Pharma S A S History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
WO2021038590A1 (en) 2019-08-30 2021-03-04 Mylan Laboratories Limited Novel polymorph of ribociclib succinate
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
US12479825B2 (en) 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
AU2020405427B2 (en) * 2019-12-16 2025-01-09 Lunella Biotech, Inc. Selective CDK4/6 inhibitor cancer therapeutics
CN118652252A (zh) 2019-12-16 2024-09-17 卢内拉生物技术有限公司 选择性cdk4/6抑制剂型癌症治疗药物
CA3164117A1 (en) 2019-12-18 2021-06-24 Crinetics Pharmaceuticals, Inc. Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
JP2023508357A (ja) 2019-12-23 2023-03-02 アキュター バイオテクノロジー インコーポレイテッド エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ
ES3032933T3 (en) 2019-12-23 2025-07-29 Crinetics Pharmaceuticals Inc Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
US20230118053A1 (en) * 2020-03-27 2023-04-20 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
EP4141004A4 (en) * 2020-05-12 2023-08-23 Suzhou Alphama Biotechnology Co., Ltd. POLYCYCLIC AMIDE DERIVATIVE SERVING AS A CDK9 INHIBITOR, METHOD FOR PREPARING IT AND ITS USE
EP4140997A4 (en) * 2020-05-12 2023-09-06 Suzhou Alphama Biotechnology Co., Ltd. PYRIDINE ACETAMIDE DERIVATIVE AS CDK INHIBITOR, PREPARATION METHOD AND USE THEREOF
US20240000789A1 (en) 2020-05-12 2024-01-04 Novartis Ag Therapeutic combinations comprising a craf inhibitor
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
EP4165046B1 (en) * 2020-06-11 2025-09-17 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
IL303079A (en) 2020-11-24 2023-07-01 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
PE20240225A1 (es) 2020-11-24 2024-02-16 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
AU2022240609A1 (en) 2021-03-19 2023-09-28 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
EP4313987B1 (en) 2021-04-01 2026-01-14 KRKA, d.d., Novo mesto Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117177752A (zh) 2021-05-05 2023-12-05 诺华股份有限公司 用于治疗mpnst的化合物和组合物
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
CA3227191A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
KR20240041340A (ko) * 2021-07-27 2024-03-29 보로노이 주식회사 피롤로피리미딘 유도체 화합물 및 이의 용도
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
CN119137102A (zh) * 2022-04-08 2024-12-13 拜奥列司治疗有限公司 Cdk9抑制剂
KR20250002427A (ko) * 2022-04-08 2025-01-07 바이오렉시스 테라퓨틱스, 인크. Cdk9 억제제
AU2023271885A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
CN120112291A (zh) 2022-08-31 2025-06-06 阿尔维纳斯运营股份有限公司 雌激素受体降解剂的给药方案
WO2024086361A1 (en) * 2022-10-21 2024-04-25 Novartis Ag Molecular glue degrader compounds and uses thereof
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
AU2024234194A1 (en) 2023-03-10 2025-08-07 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
CN121057581A (zh) 2023-05-05 2025-12-02 阿斯利康(瑞典)有限公司 用于在治疗乳腺癌中使用的卡帕塞替尼、cdk4/6抑制剂和氟维司群的组合
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
EP4730355A1 (en) 2023-05-18 2026-04-22 Lumitype Medical (Huzhou) Co., Ltd. Typing system and method for hr-positive/her2-negative breast cancer
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
CN121843694A (zh) 2023-09-06 2026-04-10 阿费克斯发展有限公司 用于治疗及预防口腔癌的组合物与方法
US20250114357A1 (en) * 2023-10-10 2025-04-10 Biolexis Therapeutics, Inc. Bifunctional protac and molecular glue compounds and methods of use thereof
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer
TW202602868A (zh) 2024-04-15 2026-01-16 瑞士商諾華公司 瑞波西利的藥物組成物
WO2025235331A1 (en) * 2024-05-07 2025-11-13 Nikang Therapeutics, Inc. Bifunctional compounds containing pyrazolopyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026038120A1 (en) * 2024-08-12 2026-02-19 Novartis Ag Synthesis and crystalline forms of a cdk2 inhibitor
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
CN120441576B (zh) * 2025-07-08 2025-09-26 山东大学 一种靶向cdk4/6的化合物及其衍生的放射性示踪剂
CN120483984B (zh) * 2025-07-09 2025-10-10 山东大学 一种靶向cdk4/6的分子影像探针标记前体、探针及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140222A2 (en) * 2006-05-26 2007-12-06 Novartis Ag Pyrrolopyrimidine compounds and their uses

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
MXPA04005939A (es) * 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
ES2314224T3 (es) 2002-03-07 2009-03-16 F. Hoffmann-La Roche Ag Inhibidores pirimidina y piridina biciclicos de p38 quinasa.
MXPA05002571A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
AR045582A1 (es) 2003-09-05 2005-11-02 Neurogen Corp Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
CN1918158B (zh) 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2005085253A1 (en) 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine derivatives
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
EP1781647A2 (en) 2004-07-22 2007-05-09 Astex Therapeutics Limited Thiazole and isothiazole derivatives as protein kinase inhibitors
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
JP5118972B2 (ja) 2004-10-29 2013-01-16 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性二環式ピリミジン誘導体
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
WO2007030438A2 (en) 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
AU2006331765A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007104053A2 (en) 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
EA201001030A1 (ru) * 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
PE20091485A1 (es) 2008-02-06 2009-10-26 Novartis Ag DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140222A2 (en) * 2006-05-26 2007-12-06 Novartis Ag Pyrrolopyrimidine compounds and their uses

Also Published As

Publication number Publication date
KR101353857B1 (ko) 2014-01-21
CU24062B1 (es) 2014-12-26
JP2012500785A (ja) 2012-01-12
LTC2331547I2 (lt) 2018-09-10
FR17C1059I2 (fr) 2019-01-11
US20140135312A1 (en) 2014-05-15
LUC00048I2 (https=) 2018-01-10
ZA201100994B (en) 2011-12-28
US9416136B2 (en) 2016-08-16
HUS1700051I1 (hu) 2017-12-28
CY1115703T1 (el) 2017-01-25
LTPA2017039I1 (lt) 2017-12-11
TW201014858A (en) 2010-04-16
NO2017059I2 (no) 2017-11-13
AR073116A1 (es) 2010-10-13
JP5882371B2 (ja) 2016-03-09
SMT201500017B (it) 2015-03-05
SI2331547T1 (sl) 2014-11-28
UA103628C2 (en) 2013-11-11
PT2331547E (pt) 2014-10-29
US20110152244A1 (en) 2011-06-23
US20170183352A1 (en) 2017-06-29
US8415355B2 (en) 2013-04-09
MA32555B1 (fr) 2011-08-01
BRPI0917791B1 (pt) 2022-03-22
CR20110101A (es) 2011-06-09
CU20110040A7 (es) 2011-12-28
FR17C1059I1 (https=) 2018-02-16
CY2017042I2 (el) 2018-04-04
EP2716643A1 (en) 2014-04-09
NO2017059I1 (no) 2017-11-13
US20180155351A1 (en) 2018-06-07
NZ591176A (en) 2012-11-30
CA2734802A1 (en) 2010-02-25
CA2734802C (en) 2016-05-31
KR20130140222A (ko) 2013-12-23
JO2924B1 (en) 2015-09-15
CN102186856A (zh) 2011-09-14
UY32067A (es) 2010-03-26
KR20110052713A (ko) 2011-05-18
ECSP11010843A (es) 2011-05-31
WO2010020675A1 (en) 2010-02-25
CL2011000306A1 (es) 2011-06-24
DOP2011000057A (es) 2015-11-15
US20130184285A1 (en) 2013-07-18
EA201100355A1 (ru) 2011-10-31
CY2017042I1 (el) 2018-04-04
HRP20141018T1 (hr) 2015-02-13
US20210253578A1 (en) 2021-08-19
RS53574B1 (sr) 2015-02-27
ES2522346T3 (es) 2014-11-14
UY38935A (es) 2020-12-31
PE20110419A1 (es) 2011-07-13
CN102186856B (zh) 2014-09-24
IL211164A (en) 2016-09-29
IL211164A0 (en) 2011-04-28
CN103788100A (zh) 2014-05-14
US20100105653A1 (en) 2010-04-29
EP2331547B1 (en) 2014-07-30
TN2011000062A1 (en) 2012-09-05
BRPI0917791A2 (pt) 2019-08-13
ME01282B (me) 2013-06-20
MY150560A (en) 2014-01-30
US8685980B2 (en) 2014-04-01
EA201100355A8 (ru) 2013-09-30
AU2009284098A1 (en) 2010-02-25
EP2331547A1 (en) 2011-06-15
US8962630B2 (en) 2015-02-24
LUC00048I1 (https=) 2017-11-15
NI201100042A (es) 2011-08-09
PL2331547T3 (pl) 2015-01-30
JP5560496B2 (ja) 2014-07-30
AR111763A2 (es) 2019-08-14
DK2331547T3 (da) 2014-11-03
GEP20135785B (en) 2013-03-11
HK1156625A1 (en) 2012-06-15
CO6341561A2 (es) 2011-11-21
HN2011000542A (es) 2013-10-17
EA019094B1 (ru) 2014-01-30
US20240043428A1 (en) 2024-02-08
JP2014129361A (ja) 2014-07-10
CA2734802E (en) 2010-02-25
MX2011001879A (es) 2011-03-29
NL300909I1 (https=) 2017-11-10
NL300909I2 (nl) 2017-12-19
TWI468409B (zh) 2015-01-11

Similar Documents

Publication Publication Date Title
AU2009284098B2 (en) Pyrrolopyrimidine compounds as CDK inhibitors
AU2008333136B2 (en) Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
HK1193406A (en) Pyrrolopyrimidine compounds and their uses
HK1156625B (en) Pyrrolopyrimidine compounds as cdk inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BESONG, GILBERT; BRAIN, CHRISTOPHER THOMAS; BROOKS, CLINTON A.; CONGREVE, MILES STUART; DAGOSTIN, CLAUDIO; HE, GUO; HOU, YING; HOWARD, STEVEN; LI, YUE; LU, YIPIN; MORTENSON, PAUL; SMITH, TROY; SUNG, MOO; WOODHEAD, STEVEN; WRONA, WOJCIECH AND BAHARAT, LAGU.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BESONG, GILBERT; BRAIN, CHRISTOPHER THOMAS; BROOKS, CLINTON A.; CONGREVE, MILES STUART; DAGOSTIN, CLAUDIO; HE, GUO; HOU, YING; HOWARD, STEVEN; LI, YUE; LU, YIPIN; MORTENSON, PAUL; SMITH, TROY; SUNG, MOO; WOODHEAD, STEVEN; WRONA, WOJCIECH AND LAGU, BAHARAT

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ESONG, GILBERT; BRAIN, CHRISTOPHER THOMAS; BROOKS, CLINTON A.; CONGREVE, MILES STUART; DAGOSTIN, CLAUDIO; HE, GUO; HOU, YING; HOWARD, STEVEN; LI, YUE; LU, YIPIN; MORTENSON, PAUL; SMITH, TROY; SUNG, MOO; WOODHEAD, STEVEN; WRONA, WOJCIECH AND LAGU, BHARAT .

TH Corrigenda

Free format text: IN VOL 26 , NO 37 , PAGE(S) 4869 UNDER THE HEADING AMENDMENTS - AMENDMENTS MADE DELETE ALL REFERENCE TO 2009284098

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BESONG, GILBERT; BRAIN, CHRISTOPHER THOMAS; BROOKS, CLINTON A.; CONGREVE, MILES STUART; DAGOSTIN, CLAUDIO; HE, GUO; HOU, YING; HOWARD, STEVEN; LI, YUE; LU, YIPIN; MORTENSON, PAUL; SMITH, TROY; SUNG, MOO; WOODHEAD, STEVEN; WRONA, WOJCIECH AND LAGU, BHARAT

FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: KISQALI RIBOCICLIB

Filing date: 20171023

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: KISQALI RIBOCICLIB

Filing date: 20171023

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: KISQALI RIBOCICLIB

Filing date: 20171023

Extension date: 20321023